(R)-1-BOC-2-苄基哌嗪 | 947684-78-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: (R)-1-BOC-2-苄基哌嗪
• 中文别名: (2R)-2-(苯甲基)-1-哌嗪甲酸叔丁酯；(R)-N-1-BOC-2-苄基哌嗪；(R)-1-Boc-2-苄基哌嗪
• 英文名称: tert-butyl (R)-2-benzylpiperazine-1-carboxylate
• 英文别名: (R)-1-Boc-2-benzylpiperazine；(R)-1-tert-butoxycarbonyl-2-benzyl-piperazine；tert-butyl (2R)-2-benzylpiperazine-1-carboxylate
• CAS: 947684-78-8
• 化学式: C₁₆H₂₄N₂O₂
• 分子量: 276.379
• InChiKey: QKUHUJCLUFLGCI-CQSZACIVSA-N

物化性质

• 沸点：
  382.9±17.0 °C(Predicted)
• 密度：
  1.066

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险品运输编号：
  2735
• 危险性描述：
  H314

反应信息

• 作为反应物：
  描述：

  (R)-1-BOC-2-苄基哌嗪 在 tris-(dibenzylideneacetone)dipalladium(0) 、 三乙胺 、 sodium t-butanolate 、 2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 (R)-1-(4-(2-benzyl-4-(methylsulfonyl)piperazin-1-yl)phenyl)-6-(benzyloxy)-5,7-difluoro-1H-benzo[d][1,2,3]triazole
  参考文献：
  名称：

  WO2023/43836

  摘要：

  公开号：

文献信息

• Impact of Distinct Chemical Structures for the Development of a Methamphetamine Vaccine
  作者：Amira Y. Moreno、Alexander V. Mayorov、Kim D. Janda

  DOI：10.1021/ja108807j

  日期：2011.5.4

  (+)-Methamphetamine (METH) use and addiction has grown at alarming rates over the past two decades, while no approved pharmacotherapy exists for its treatment. Immunopharmacotherapy has the potential to offer relief through producing highly specific antibodies that prevent drug penetration across the blood-brain barrier thus decreasing reinforcement of the behavior. Current immunotherapy efforts against methamphetamine have focused on a single hapten structure, namely linker attachment at the aromatic ring of the METH molecule. Hapten design is largely responsible for immune recognition, as it affects presentation of the target antigen and thus the quality of the response. In the current paper we report the systematic generation of a series of haptens designed to target the most stable conformations of methamphetamine as determined by molecular modeling. On the basis of our previous studies with nicotine, we show that introduction of strategic molecular constraint is able to maximize immune recognition of the target structure as evidenced by higher antibody affinity. Vaccination of GIX(+) mice with six unique METH immunoconjugates resulted in high antibody titers for three particularly promising formulations (45-108 mu g/mL, after the second immunization) and high affinity (82, 130, and 169 nM for ME2, MH6, and MH7 hapten-based vaccines, respectively). These findings represent a unique approach to the design of new vaccines against methamphetamine abuse.

  （+）-甲基苯丙胺（METH）的使用和成瘾在过去二十年中以惊人的速度增长，然而目前尚无批准用于治疗的药物疗法。免疫药理学有望通过产生高度特异性的抗体来提供缓解，这些抗体可以阻止药物穿透血脑屏障，从而减少行为的强化。针对甲基苯丙胺的免疫治疗研究一直集中在单一的半抗原结构上，即连接物附着在METH分子的芳香环上。半抗原设计对免疫识别至关重要，因为它影响目标抗原的呈递，从而影响免疫反应的质量。在本文中，我们报告了系统生成一系列半抗原的设计，旨在靶向甲基苯丙胺通过分子建模确定的最稳定构象。基于我们之前对尼古丁的研究，我们表明引入战略性的分子约束能够最大化对目标结构的免疫识别，这一点通过更高的抗体亲和力得到了证明。用六种独特的METH免疫偶联物对GIX(+)小鼠进行免疫接种，结果三种特别有前途的制剂在第二次免疫后产生了高抗体滴度（45-108 μg/mL），并且表现出高亲和力（ME2、MH6和MH7半抗原基疫苗的亲和力分别为82、130和169 nM）。这些发现代表了设计新型甲基苯丙胺滥用疫苗的独特方法。
• IL-17 Ligands And Uses Thereof
  申请人：DICE Molecules SV LLC.

  公开号：US20200247785A1

  公开（公告）日：2020-08-06

  Provided herein are novel ligands and pharmaceutical compositions thereof which modulate IL-17A. Also provided are methods for preparing the IL-17A modulators. Such compounds may be useful in the treatment and/or prevention of, for example, inflammation, cancer or autoimmune disease.

  本文提供了新型配体及其药物组合物，可调节IL-17A。还提供了制备IL-17A调节剂的方法。这些化合物可能在治疗和/或预防炎症、癌症或自身免疫疾病等方面有用。
• Kinase inhibitors
  申请人：Chan Tin-Yau

  公开号：US20080004257A1

  公开（公告）日：2008-01-03

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease.

  具有公式（I）一般结构的化合物，或其药学上可接受的盐、溶剂或酯，可用于治疗免疫缺陷、癌症、心血管疾病、内分泌紊乱、帕金森病、代谢性疾病、肿瘤发生、阿尔茨海默病、心脏病、糖尿病、神经退行性疾病、炎症、肾脏疾病、动脉硬化和气道疾病等疾病、障碍或状况的治疗。
• Azaquinazoline Inhibitors of Atypical Protein Kinase C
  申请人：Cancer Research Technology Limited

  公开号：US20160102094A1

  公开（公告）日：2016-04-14

  The present application provides a compound of formula (1) or a salt thereof, wherein R 7 , R 8 , R 9 , G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.

  本申请提供了一个公式（1）的化合物或其盐，其中R7、R8、R9、G和X的定义如本文所述。本申请进一步描述了包含这些化合物的组合物。公式（I）的化合物及其盐具有aPKC抑制活性，并可用于治疗增殖性疾病。
• Chemical mechanical planarization for tungsten-containing substrates
  申请人：AIR PRODUCTS AND CHEMICALS, INC.

  公开号：EP2779217A2

  公开（公告）日：2014-09-17

  Chemical mechanical polishing (CMP) compositions for polishing tungsten or tungsten-containing substrates comprise an abrasive, at least one solid catalyst, a chemical additive selected from the groups consisting of piperazine derivatives, salts of cyanate, and combinations thereof; and a liquid carrier. Systems and processes use the aqueous formulations for polishing tungsten or tungsten-containing substrates.

  用于抛光钨或含钨基材的化学机械抛光（CMP）组合物包括磨料、至少一种固体催化剂、一种选自哌嗪衍生物、氰酸盐及其组合的化学添加剂；以及一种液体载体。系统和工艺使用水性制剂抛光钨或含钨基材。